• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Gastroenterology

No difference in survival after laparoscopic versus open liver resection for colorectal metastases

byThomas SuandDeepti Shroff, DMD, MS
December 3, 2020
in Gastroenterology, Oncology, Surgery
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. The rates of 5-year overall survival were found to differ by less than a percentage point between patients in the laparoscopic group and those in the open group.

2. Recurrence-free survival at 5 years was over 5% higher in the open group, but this difference was statistically insignificant as well.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Colorectal cancer (CRC) is the second leading cause of cancer death worldwide. Roughly half of patients with CRC eventually develop liver metastases, which are increasingly responsive to curative resection thanks to advances in diagnostics, oncologic treatment, and surgical techniques. Laparoscopic liver surgery is minimally invasive and has been shown in numerous retrospective studies as well as the randomized controlled OSLO-COMET trial to improve short-term outcomes relative to open surgery, but the long-term effects of each approach were unclear. In this OSLO-COMET extension study, no differences in recurrence-free survival or overall survival were detected between patients in the laparoscopic group and patients in the open group at 5 years. Median recurrence-free survival was also similar between groups. However, given the limited sample size, the possibility of small to moderate differences in survival in either direction could not be excluded. This study was conducted at a single high-volume surgical center, which minimized case-to-case variation, but this design also limited generalizability to other, non-expert settings. Future multicenter randomized controlled trials may reveal more insight regarding noninferiority and other specific secondary endpoints.

Click here to read the study in the Annals of Internal Medicine

Relevant Reading: Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial

RELATED REPORTS

WGS Oncodetect showed higher recurrence sensitivity than WES Oncodetect in colorectal cancer

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

In-Depth [randomized controlled trial]: Between February 2012 and February 2016, 280 patients with colorectal liver metastases were assigned using block randomization to receive either laparoscopic or open parenchyma-sparing liver resection (fewer than 3 consecutive liver segments). Patients who required formal hemihepatectomy, vessel or bile duct reconstruction, or ablation were excluded. Survival analysis was performed in January 2020, and median overall survival was 80 months (95% CI, 63 to 97 months) in the laparoscopic surgery group and 70 months (95% CI, 48 to 92 months) in the open surgery group (hazard ratio [HR], 0.93; 95% CI, 0.67 to 1.30). Overall survival rates for 1, 3, and 5 years were 94%, 71%, and 54%, respectively, in the laparoscopic group and 93%, 71%, and 55% in the open group (between-group difference at 5 years, 0.5 percentage point; 95% CI, −11.3 to 12.3 percentage points). Median recurrence-free survival was 17 months (95% CI, 10 to 23 months) in the laparoscopic group and 16 months (95% CI, 8 to 24 months) in the open group (HR, 1.09; 95% CI, 0.80 to 1.49; P = 0.57); the 5-year recurrence-free survival rate was slightly higher in the open surgery group (36% vs. 30%; 95% CI, −6.7 to 18.7 percentage points). A total of 60 patients required repeat surgery for recurrent liver metastases.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: colorectal cancerhemihepatectomymetastatic cancer
Previous Post

Sotagliflozin reduces cardiovascular risk for patients with diabetes and worsening heart failure

Next Post

Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis

RelatedReports

An envelope is being held with a calendar and an illustration of the colon in the background, indicating a reminder for colorectal screening.
2MM Trial Briefs

WGS Oncodetect showed higher recurrence sensitivity than WES Oncodetect in colorectal cancer

October 26, 2026
Radiation plus hormone therapy may improve prostate cancer survival
Chronic Disease

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

July 22, 2026
Chronic Disease

Enfortumab vedotin plus pembrolizumab is more effective than platinum-based chemotherapy in metastatic urothelial carcinoma

July 9, 2026
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Male sex and hispanic ethnicity are associated with increased risk of early-onset colorectal cancer

June 29, 2026
Next Post

Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis

Neuraxial anesthesia associated with decreased 30-day all-cause mortality for patients undergoing lower limb revascularization

Acamprosate found to be one of few effective and tolerable interventions for alcohol dependence

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
  • In a phase 3 trial, tirzepatide reduced BMI versus placebo in adolescents with obesity and obesity-related complications
  • Continuation of immunotherapy after immune checkpoint inhibitor-induced myocarditis in patients with lung cancer may be safe and effective
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.